Key result
Stereoelectroencephalography-guided radiofrequency thermocoagulation achieved a pooled 1-year seizure-free rate of 37.8% (95% CI 24.7-50.8%) in patients with drug-resistant epilepsy.
Why the study?
Most evidence for SEEG-guided radiofrequency thermocoagulation in focal drug-resistant epilepsy is limited to small observational studies, warranting an updated meta-analysis to assess its effectiveness.
Does SEEG-RFTC improve seizure outcomes in patients with focal drug-resistant epilepsy?
Meta-Analysis (n=437)
Does SEEG-RFTC improve seizure outcomes in patients with focal drug-resistant epilepsy?
SEEG-RFTC is a potentially effective therapeutic option for seizure control in patients with drug-resistant epilepsy, with higher efficacy in nodular heterotopia and hippocampal sclerosis.
May offer seizure control option in select DRE patients; leaves open confirmation by prospective trials.
OBJECTIVE: In patients with focal drug-resistant epilepsy (DRE), resective epilepsy surgery correlates with high rates of remission. However, in cases where the epileptic region is deemed surgically inaccessible, or when it involves a complex network, stereoelectroencephalography-guided radiofrequency thermocoagulation (SEEG-RFTC) might be an alternative therapeutic strategy. However, most of the available evidence is limited to small observational studies. An updated meta-analysis is warranted to provide a comprehensive assessment of SEEG-RFTC in patients with DRE. METHODS: Databases were searched until September 9, 2023 to identify published studies reporting on the effectiveness of SEEG-RFTC in patients with DRE. The primary outcomes of interest were the 1-year seizure-freedom rate and response rate (50% seizure frequency decrease from baseline). These outcomes were pooled using the inverse variance and a random-effects model. RESULTS: We screened 182 articles and included 16 retrospective cohort studies. A total of 437 unique patients from 12 nonoverlapping cohorts were analyzed for seizure and complication outcomes. The pooled seizure-free rate after 1 year was 37.8% (95% confidence interval [CI] = 24.7%-50.8%), whereas the seizure response rate after 1 year was 69.7% (95% CI = 52.7%-86.7%). There was high heterogeneity among the included studies. Subgroup analysis revealed that patients with nodular heterotopia achieved higher rates of seizure freedom (57.1%, 95% CI = 38.8%-75.5%) compared to those with cortical dysplasia (CD) and magnetic resonance imaging-negative conditions. Furthermore, hippocampal sclerosis patients exhibited higher seizure freedom rates (66.7%, 95% CI = 49.8%-83.5%) than those with CD (12.0%, 95% CI = .0%-24.7%). SIGNIFICANCE: SEEG-RFTC might be an effective therapeutic option for seizure control in patients with DRE who undergo SEEG for DRE workup. The role of SEEG-RFTC as a potential adjunct therapy to laser interstitial thermal therapy or surgical resection should be explored. This study highlights the need for well-designed clinical trials to compare SEEG-guided RFTC with other therapeutic modalities.
No takes yet. Share an insight, caveat, or question.
Pichardo‐Rojas et al. (2025) conducted a meta-analysis in focal drug-resistant epilepsy (DRE) (n=437). Stereoelectroencephalography-guided radiofrequency thermocoagulation (SEEG-RFTC) was evaluated on 1-year seizure-freedom rate (95% CI 24.7-50.8). Stereoelectroencephalography-guided radiofrequency thermocoagulation achieved a pooled 1-year seizure-free rate of 37.8% (95% CI 24.7-50.8%) in patients with drug-resistant epilepsy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: